Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Cost of Revenue (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Cost of Revenue for 10 consecutive years, with $26.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 78.94% year-over-year to $26.5 million, compared with a TTM value of $72.9 million through Dec 2025, up 37.75%, and an annual FY2025 reading of $72.9 million, up 37.75% over the prior year.
  • Cost of Revenue was $26.5 million for Q4 2025 at Amicus Therapeutics, up from $19.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $26.5 million in Q4 2025 and bottomed at $6.5 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $11.8 million, with a median of $11.3 million recorded in 2023.
  • The sharpest move saw Cost of Revenue decreased 25.97% in 2023, then soared 95.43% in 2024.
  • Year by year, Cost of Revenue stood at $7.9 million in 2021, then rose by 19.53% to $9.4 million in 2022, then grew by 20.67% to $11.3 million in 2023, then soared by 31.01% to $14.8 million in 2024, then skyrocketed by 78.94% to $26.5 million in 2025.
  • Business Quant data shows Cost of Revenue for FOLD at $26.5 million in Q4 2025, $19.5 million in Q3 2025, and $15.2 million in Q2 2025.